Your topics. New publications.

A compact browser notification when there’s something new. At most once a day — no account needed.

What interests you?

Optional and switchable off here at any time. We save your selected topics and device subscription; no email address is required. Privacy

Search the harborEN/DEAccount
Video library· Pulmonary Fibrosis FoundationAudio: English

The Effects of Senolytics in Animal Models of PF | Cory Hogaboam, PhD

Thumbnail from YouTube. Playing loads the YouTube player.

History & recommendationsOff

Keep recently viewed content on this browser. Your history stays on this device and is never sent to Harbor. Videos you play can also help order related video recommendations.

Up to 120 items · 90 days. Turning this off deletes the history.
Open saved items & history →

About this video

Creator description · original textText language: English

Cory Hogaboam, PhD of Cedars-Sinai discusses the several mechanisms that appear to account for cellular senescence in IPF as well as the benefits, consequences, and future challenges of cellular senescence. Social media platforms - Twitter - @PFFORG Facebook - @PFFORG Instagram - @PFFORG LinkedIn- Pulmonary Fibrosis Foundation Please note that any information contained in this presentation is for informational and/or educational purposes only. It is not intended to be a substitute for professional medical advice. Always consult your personal physician or health care provider with any questions you may have regarding your specific medical condition. This presentation is protected by U.S. and International copyright laws. Reproductions and distribution of this presentation without written permission from the Pulmonary Fibrosis Foundation is prohibited. © 2020 Pulmonary Fibrosis Foundation

Pulmonary Fibrosis Foundation · 19 min · Source published: 2020-02-13

Added to Harbor: 10/23/2026

Original on YouTube ↗

Automatically categorized source. Creator statements are not an independent evidence review or personal medical guidance.

Discussion

Community discussions

0 topics

Member contributions. Share sources, disclose commercial interests, and avoid personal medical or dosing advice.

Loading…